Allogeneic Hematopoietic Stem Cell Transplantation
Pipeline by Development Stage
Drug Modality Breakdown
On Market (1)
Approved therapies currently available
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 9,291 patients across 50 trials
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease
Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis
Triple Combination Therapy in High Risk Crohn's Disease (CD)
Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
Vedolizumab for the Treatment of Collagenous Gastritis
Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Vedolizumab Induction May Prevent Celiac Enteritis
Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease
A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT
A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants
A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants
A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants
A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants
Synergistic Effect of Vedolizumab and Pentoxifylline
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration